Perineural Dexmedetomidine and Femoral Nerve Block

Cairo University (CU)

Status and phase: Unknown; Phase 4

Conditions: Onset and Duration of Sensory and Motor Block of Femoral Nerve,; Visual Analogue Pain Scores,; Time to First Request of Rescue Analgesics,; Total Morphine Consumption in 24 Hours

Treatments: Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Study type: Interventional

Funder types: Other

Identifiers

NCT01964040

N-38-2013

Details and patient eligibility

About

The duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. Alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. Dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. To the best of our knowledge, the use of Dexmedetomidine as adjuvant to local anesthetic was not previously reported for femoral nerve block.

Enrollment: 45 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients with ASA physical status I or II, scheduled for diagnostic knee arthroscopy

Exclusion criteria

• Patients who are refusing regional block, patients with diabetic peripheral neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture site, and history of allergic reaction to study medications

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

45 participants in 3 patient groups, including a placebo group

group B: control bupivacaine group

Placebo Comparator group

Description:

Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.

Treatment:

Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Group B-peri-DEX: Peri-neural Dexmedetomidine

Experimental group

Description:

Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline

Treatment:

Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block

Group B-sys-DEX:Systemic Dexmedetomidine

Active Comparator group

Description:

Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.

Treatment:

Drug: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block